June 24, 2021 12:22 PM EDT

Covid-19 manufacturing roundup: Smuggled remdesivir seized en route to Mexico; As Sputnik awaits WHO approval, a Russian plant raises concerns

Josh Sullivan

Unauthorized versions of the Covid-19 drug remdesivir bound for distribution in Mexico were seized by US federal authorities, The Wall Street Journal

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 manufacturing roundup: Smuggled remdesivir seized en route to Mexico; As Sputnik awaits WHO approval, a Russian plant raises concerns

Josh Sullivan

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Covid-19 man­u­fac­tur­ing roundup: Smug­gled remde­sivir seized en route to Mex­i­co; As Sput­nik awaits WHO ap­proval, a Russ­ian plant rais­es con­cerns

Josh Sullivan

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Covid-19 manufacturing roundup: Smuggled remdesivir seized en route to Mexico; As Sputnik awaits WHO approval, a Russian plant raises concerns

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Novartis to cut 139 jobs in NJ as part of commercial refocus

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy